Form 10-Q Hims & Hers Health, Inc. For: Sep 30

Go back to Form 10-Q Hims & Hers Health, Inc. For: Sep 30

Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'

November 4, 2025 8:06 AM EST

Jefferies analyst Glen Santangelo lowered the price target on Hims and Hers (NYSE: HIMS) to $48.00 (from $51.00) while maintaining a Hold rating.

The analyst comments "HIMS delivered a solid Q3, with revs, EBITDA, & EPS beating Street ests by 3%, 15%, & 30% respectively. EBITDA margins of 13.1% beat Street... More

Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'

November 4, 2025 5:13 AM EST

Needham analyst Ryan MacDonald reiterated a Hold rating on Hims and Hers (NYSE: HIMS).

The analyst comments "We are reiterating our Hold rating on Hims & Hers Health (HIMS) following the company's earnings print in which a 3Q beat was offset... More

BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'

November 4, 2025 4:35 AM EST

BTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).

The analyst comments "On Monday, 11/3/25 AMC, HIMS reported good 3Q:25 results. Revenue of $599M +49% y/y exceeded BTIG / consensus / guidance of $580.1M / $580M / $570M-$590M and adjusted EBITDA of $78.4M +53% y/y also came in well ahead of BTIG / consensus / guidance of $70.5M / $68M / $60M-$70M. HIMS... More